BioMarin Pharmaceutical (BMRN) revenue
BioMarin Pharmaceutical (BMRN) reported revenue of $3.22B in fiscal 2025 (the year ended December 31, 2025). That is 12.9% higher than the $2.85B of fiscal 2024. Figures as of 18 Nov 2026, 11:44 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $3.22B
- Change on fiscal 2024
- +12.9%
- Growth, 5 years
- +11.6% a year
- Growth, 10 years
- +13.7% a year
- Highest on record
- $3.22Bfiscal 2025
- Lowest on record
- $296.49Mfiscal 2008
- Fiscal years on record
- 182008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
BioMarin Pharmaceutical revenue, in more detail
Over the five fiscal years to 2025 revenue grew at a compound 11.6% a year; over ten years the rate was 13.7% a year. Across the 18 fiscal years on record (2008–2025), the highest was $3.22B in fiscal 2025 and the lowest $296.49M in fiscal 2008.
Revenue by fiscal year
BioMarin Pharmaceutical revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $3.22B | 12.9% up | |
| 2024 | $2.85B | 18.0% up | |
| 2023 | $2.42B | 15.4% up | |
| 2022 | $2.10B | 13.5% up | |
| 2021 | $1.85B | 0.8% down | |
| 2020 | $1.86B | 9.2% up | |
| 2019 | $1.70B | 14.3% up | |
| 2018 | $1.49B | 13.5% up | |
| 2017 | $1.31B | 17.6% up | |
| 2016 | $1.12B | 25.5% up | |
| 2015 | $889.90M | 18.8% up | |
| 2014 | $749.28M | 36.6% up | |
| 2013 | $548.49M | 9.5% up | |
| 2012 | $500.72M | 13.5% up | |
| 2011 | $441.36M | 17.3% up | |
| 2010 | $376.27M | 15.9% up | |
| 2009 | $324.66M | 9.5% up | |
| 2008 | $296.49M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| Universal Health Services UHS | $17.36B | 2025 |
| Repligen RGEN | $738.26M | 2025 |
| Bio-Techne TECH | $1.22B | 2026 |
| BioMarin Pharmaceutical BMRN | $3.22B | 2025 |
| Avantor AVTR | $6.55B | 2025 |
| Ensign Group ENSG | $5.06B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
BioMarin Pharmaceutical, figure by figure
- BioMarin Pharmaceutical market cap
- BioMarin Pharmaceutical earnings
- BioMarin Pharmaceutical earnings per share (EPS)
- BioMarin Pharmaceutical P/E ratio
- BioMarin Pharmaceutical P/S ratio
- BioMarin Pharmaceutical P/B ratio
- BioMarin Pharmaceutical free cash flow
- BioMarin Pharmaceutical operating margin
- BioMarin Pharmaceutical dividend
- BioMarin Pharmaceutical shares outstanding
- BioMarin Pharmaceutical total debt
- BioMarin Pharmaceutical cash on hand
- BioMarin Pharmaceutical total assets
- BioMarin Pharmaceutical return on equity (ROE)
- BioMarin Pharmaceutical return on invested capital (ROIC)
BioMarin Pharmaceutical (BMRN) overview: price, valuation and scorecardAll health care companies by market value
BioMarin Pharmaceutical revenue: questions and answers
What is BioMarin Pharmaceutical's revenue?
BioMarin Pharmaceutical (BMRN) reported revenue of $3.22B in fiscal 2025 (the year ended December 31, 2025). That is 12.9% higher than the $2.85B of fiscal 2024.
What is the growth rate of BioMarin Pharmaceutical's revenue?
Over the five fiscal years to 2025 revenue grew at a compound 11.6% a year; over ten years the rate was 13.7% a year.
What are the highest and lowest revenue figures on record for BioMarin Pharmaceutical?
Across the 18 fiscal years on record (2008–2025), the highest was $3.22B in fiscal 2025 and the lowest $296.49M in fiscal 2008.
How is BioMarin Pharmaceutical's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For BioMarin Pharmaceutical it is on record here for 18 fiscal years, 2008 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “BioMarin Pharmaceutical (BMRN) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/BMRN/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.